Annemie Deiteren
Head of Early Clinical & Experimental Therapeutics Sanofi
Board-certified MD PhD & clinical pharmacologist with 10+ years of experience in R&D, both in academia and industry. As group leader for the Early Clinical and Experimental Therapeutics team, my expertise is in building the early development strategy for compounds in the immunology space with a focus an human target validation, early patient data and robust Go/No Go decision making. This includes the design and medical and scientific oversight of First-in-Man, Proof-of-Mechanism and Proof-of-Concept studies with end-to-end thinking while ensuring strategic alignment with therapeutic areas in research and development and addressing dynamic portfolio needs. Recognized for my collaborative leadership style and strategic vision, I empower high-performing teams to deliver innovative development strategies. Passionate about advancing science to improve patient outcomes and shape the future of medicine
Seminars
- Validating inflammatory pathways through translational in vivo models, including inducible skin challenge systems that allow early proof-of-mechanism testing before committing to full patient trials
- Benchmarking multi-pathway modulation against known therapeutic mechanisms to differentiate biological effects and prioritize the most promising targets for further development
- Using early translational pharmacology and experimental therapeutic studies to inform clinical strategy, generating mechanistic evidence that strengthens regulatory discussions and supports progression toward Phase II trials in indications such as HS
